ROCKET PHARMACEUTICALS INC (RCKT) — insider trading
Health Care · NASDAQ
ROCKET PHARMACEUTICALS INC (RCKT) has 49 reported SEC Form 4 insider transactions in our data, including 15 open-market sales among the most recent 49 (latest 2026-09-11).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Wilson Martin | Officer (General Counsel) | Open-market sale | 75,364 | $3.40 | $256.5K | Form 4 |
| 2026-08-18 | Shah Gaurav | Officer (CEO) | Open-market sale | 2,293 | $3.38 | $7.8K | Form 4 |
| 2026-08-18 | Wilson Martin | Officer (General Counsel) | Open-market sale | 631 | $3.38 | $2.1K | Form 4 |
| 2026-08-13 | Wilson Martin | Officer (General Counsel) | Open-market sale | 3,493 | $3.38 | $11.8K | Form 4 |
| 2026-08-13 | Shah Gaurav | Officer (CEO) | Open-market sale | 2,837 | $3.38 | $9.6K | Form 4 |
| 2026-08-11 | Chaudhuri Sarbani | Officer (See Remarks) | Open-market sale | 4,701 | $3.50 | $16.4K | Form 4 |
| 2026-08-11 | Stevens Christopher James | Officer (Chief Operating Officer) | Open-market sale | 36,658 | $3.50 | $128.3K | Form 4 |
| 2026-08-03 | SOUTHWELL DAVID P | Director | Other acquisition or disposition | 150,000 | — | $0 | Form 4 |
| 2026-08-03 | Stevens Christopher James | Officer (Chief Operating Officer) | Grant / award / vesting (derivative) | 101,428 | — | $0 | Form 4 |
| 2026-08-03 | Stevens Christopher James | Officer (Chief Operating Officer) | Grant / award / vesting | 73,313 | — | $0 | Form 4 |
| 2026-06-18 | BOESS CARSTEN | Director | Grant / award / vesting (derivative) | 64,860 | — | $0 | Form 4 |
| 2026-06-18 | BOESS CARSTEN | Director | Grant / award / vesting | 22,862 | — | $0 | Form 4 |
| 2026-06-18 | SOUTHWELL DAVID P | Director | Grant / award / vesting (derivative) | 64,860 | — | $0 | Form 4 |
| 2026-06-18 | SOUTHWELL DAVID P | Director | Grant / award / vesting | 22,862 | — | $0 | Form 4 |
| 2026-06-18 | Malik Fady Ibraham | Director | Grant / award / vesting (derivative) | 64,860 | — | $0 | Form 4 |
| 2026-06-18 | Malik Fady Ibraham | Director | Grant / award / vesting | 22,862 | — | $0 | Form 4 |
| 2026-06-18 | Dolsten Mikael | Director | Grant / award / vesting (derivative) | 64,860 | — | $0 | Form 4 |
| 2026-06-18 | Dolsten Mikael | Director | Grant / award / vesting | 22,862 | — | $0 | Form 4 |
| 2026-06-18 | Fong Peter | Director | Grant / award / vesting (derivative) | 64,860 | — | $0 | Form 4 |
| 2026-06-18 | Fong Peter | Director | Grant / award / vesting | 22,862 | — | $0 | Form 4 |
| 2026-06-18 | WONG RODERICK | Director, 10% owner | Grant / award / vesting (derivative) | 78,960 | — | $0 | Form 4 |
| 2026-06-18 | WONG RODERICK | Director, 10% owner | Grant / award / vesting | 27,832 | — | $0 | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Grant / award / vesting (derivative) | 9,091 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Grant / award / vesting (derivative) | 24,899 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Grant / award / vesting (derivative) | 16,061 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Grant / award / vesting (derivative) | 15,002 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Grant / award / vesting (derivative) | 51,509 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 24,545 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 49,798 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 28,910 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 27,003 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 18,000 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 18,000 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 2,000 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 20,000 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 10,000 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 20,000 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 10,000 | — | — | Form 4 |
| 2026-05-26 | Militello John | Officer (See Remarks) | Disposition to the issuer (derivative) | 10,000 | — | — | Form 4 |
| 2026-05-21 | Shah Gaurav | Officer (CEO) | Option exercise / conversion (derivative) | 76,490 | $1.69 | $129.3K | Form 4 |
| 2026-05-21 | Shah Gaurav | Officer (CEO) | Open-market sale | 55,684 | $3.09 | $171.8K | Form 4 |
| 2026-05-21 | Shah Gaurav | Officer (CEO) | Option exercise / conversion | 76,490 | $1.69 | $129.3K | Form 4 |
| 2026-05-19 | Militello John | Officer (See Remarks) | Open-market sale | 384 | $3.01 | $1.2K | Form 4 |
| 2026-05-19 | Wilson Martin | Officer (General Counsel) | Open-market sale | 662 | $3.01 | $2.0K | Form 4 |
| 2026-05-19 | Shah Gaurav | Officer (CEO) | Open-market sale | 2,409 | $3.01 | $7.3K | Form 4 |
| 2026-05-13 | Militello John | Officer (See Remarks) | Open-market sale | 855 | $3.61 | $3.1K | Form 4 |
| 2026-05-13 | Shah Gaurav | Officer (CEO) | Open-market sale | 2,728 | $3.61 | $9.8K | Form 4 |
| 2026-05-13 | Wilson Martin | Officer (General Counsel) | Open-market sale | 3,361 | $3.61 | $12.1K | Form 4 |
| 2026-05-07 | Chaudhuri Sarbani | Officer (See Remarks) | Open-market sale | 17,650 | $3.84 | $67.7K | Form 4 |
Ask the chat about RCKT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ROCKET PHARMACEUTICALS INC (RCKT).
Last updated 2026-09-11 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.